Search
Displaying 701–710 of 851 results for “vision connection”
-
Stories That Move Us - DIY success campaigns
-
DIY Fundraising Options
-
Foundation News
The partnership will formalize an ongoing commitment by both companies to accelerate the development of treatments and cures for retinal diseases, while prioritizing a patient-centric approach.
-
Atsena Receives $150 Million in New Financing to Advance XLRS and Preclinical Gene Therapy Programs
Research NewsThe company has reported encouraging results from its LCA1 and XLRS gene therapy clinical trials.
-
Neurotech’s Encapsulated Cell Technology Receives FDA Approval for Treatment of MacTel
Research NewsThe technology was previously funded by the Foundation for the treatment of retinitis pigmentosa and dry age-related macular degeneration.
-
Foundation News
With nearly two decades of leadership in vision and neuroscience research and a committed tenure with the Foundation, Dr. Laster will spearhead the Foundation’s scientific strategy in her new role.
-
Adverum Advancing Wet AMD Gene Therapy into Phase 3 Clinical Trials
Research NewsIn earlier clinical trials, the emerging gene therapy greatly reduced the treatment burden associated with injections of approved anti-VEGF therapies.
-
Foundation Fighting Blindness Celebrates 20 Years of VisionWalk
Foundation NewsVisionWalk has been uniting communities across the country for 20 years, all while raising awareness and funding research driving treatments and cures for blinding diseases.
-
Pioneering Delivery Strategies for Blinding Diseases Therapy and Inspiring Women in Science
Beacon StoriesInternational Day of Women and Girls in Science is celebrated globally to recognize the critical role women play in science, technology, engineering, and mathematics. To honor this vital day, the Foundation is thrilled to spotlight Dr. Renee Ryals, PhD, a remarkable scientist at the Casey Eye Institute, Oregon Health & Science University.
-
Foundation News
The free, online event at 7 p.m. ET on March 13, 2025, will feature presentations from Christine Kay, MD, Vitreoretinal Associates in Gainesville, Florida, and Thomas Mendel, MD, PhD, Ohio State University Wexner Medical Center.
